Biotech execs wrestle with 'nightmare' of developing digital biomarkers; depression hits new high among Americans

Many drugmakers are still in the earliest stages of incorporating digital endpoints into the plodding process of drug development.

May 17, 2023 Check out STAT+

Sponsored By

Courtesy Regeneron STAT+ | Biotech and pharma execs wrestle with the 'nightmare' of developing digital biomarkers The impact of wearables clinical trials for drugs remains largely hypothetical, in part because digital biomarkers are difficult to develop. By Mario Aguilar Depression hits new high among Americans, per survey More than a quarter of American adults are depressed, a 10% surge from nearly a decade ago, according to the latest Gallup survey. By Sarah Owermohle Opinion: Do chatbots have more time to be empathetic than physicians? An oncologist discusses the idea that AI, like ChatGPT, could potentially answer patient questions more efficiently than real doctors. By Torie Bosch Adobe STAT+ | A new startup looks to turn the workhorse of gene therapy against cancer AAV viruses have long been used to shuttle genes into patients with genetic diseases. A new startup wants to use them to tackle cancer. By Jason Mast Opinion: Starting breast cancer screening at 40 saved my life Reluctant to fit another appointment into my busy life, I almost didn't start getting mammograms in my 40s. By Heather Landy Opinion: New draft recommendations for mammograms take a one-size-fits-all approach The new recommendations are supposed to maximize lives saved while helping to address inequities in care. Will they work? By Lydia E. Pace and Nancy L. Keating Shuran Huang/The New York Times STAT+ | Could an upcoming Supreme Court case make the FDA slower? The FDA could take longer to write regulations and make decisions if the U.S. Supreme Court rules against a long-standing legal doctrine. By John Wilkerson STAT+ | PTC Therapeutics's PKU drug succeeds in trial, but bigger hurdles for company are ahead In PKU, patients can't break down the amino acid phenylalanine, resulting in intellectual disability, memory problems, and other issues. By Matthew Herper

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser